KR870000282A - 글리세롤 유도체의 제조방법 - Google Patents

글리세롤 유도체의 제조방법 Download PDF

Info

Publication number
KR870000282A
KR870000282A KR1019860004802A KR860004802A KR870000282A KR 870000282 A KR870000282 A KR 870000282A KR 1019860004802 A KR1019860004802 A KR 1019860004802A KR 860004802 A KR860004802 A KR 860004802A KR 870000282 A KR870000282 A KR 870000282A
Authority
KR
South Korea
Prior art keywords
group
alkyl
residues
formula
butoxy
Prior art date
Application number
KR1019860004802A
Other languages
English (en)
Inventor
바르너 리하르트
부리 카스파르
카쌀 쟝-마리
하드파리 파울
허치 죠르쥬
뮐러 클라우스
Original Assignee
장-자크 오가이, 노베르 아. 코똥
에프. 호프만-라롯슈 앤드 캄파니 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장-자크 오가이, 노베르 아. 코똥, 에프. 호프만-라롯슈 앤드 캄파니 아크티엔 게젤샤프트 filed Critical 장-자크 오가이, 노베르 아. 코똥
Publication of KR870000282A publication Critical patent/KR870000282A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음.

Description

글리세롤 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

1. 일반식(Ⅱ)의 화합물을 일반식 NR의 아민과 반응시키거나; 일반식(Ⅲ)의 화합물을 일반식(Ⅳ-1) 또는 (Ⅳ-2)의 산 또는 이의 반응성 유도체, 또는 일반식 (Ⅴ-1) 또는 (Ⅴ-2)의 이소시아네이트 또는 일반식 (Ⅵ-1) 또는 (Ⅵ-2)의 이미다졸리드와 반응시키거나; 일반식(Ⅶ)의 화합물을 C1-6-알킬 할라이드와 반응시킴을 특징으로 하여, 일반식(Ⅰ)의 글리세롤유도체 및 이의 수화물을 제조하는 방법.
상기식에서,
잔기 R¹, R²및 R³중의 하나는 일반식 OY¹또는 -X1-CO-(A¹)-Z¹의 그룹 U이고, 다른 하나의 잔기는 일반식 OY²또는 -X²-CO - (A²)P- Z²의 그룹 V이며, 나머지 잔기는 일반식 - X³T - (C2-6-알킬렌) - N+RA-의 그룹 W이고 ; X¹,X²및 X³중의 하나는 산소 또는 그룹 NQ¹이고 나머지 둘은 산소이며 ; Y¹은 C10-26 -알킬 또는 C10-26-알케닐이고 ; Y²는 C1-6-알킬, C2-6-알케닐, C2-6-사이클로알킬, C3-6-사이클로알케닐, 페닐, 벤질 또는 2-테트라하이드로피라닐이며 ; A¹및 A²는 산소 또는 그룹 NQ²이고 ; n 및 p는 각기 독립적으로 1 또는 0의 수이며 ; Z¹은C9-25-알킬 또는 C9-25-알케닐이고 ; Z²는 C1-5-알킬, C2-5-알케닐 또는 페닐을 나타내거나, A²가 산소가 아닐 경우에, Z²는 또한 수소를 나타내며 ; T는 카보닐, COO 또는 CONQ³를 나타내거나, X³가 산소일 경우에, T는 또한 메틸렌을 나타내고 ; Q¹, Q²및 Q³는 각기 독립적으로 수소, C1-4-알킬, C3-6-사이클로알킬 또는 페닐이며 ; A-는 강산의 음이온이고 ; -N+R은 그룹-N+(Y³,Y⁴,Y )이거나, X¹,X²,X³,A¹,A²및 T중의 적어도 하나가 치환된 N-원자를 함유할 경우에-N+R은 또한 임으로 추가의 헤테로원자 O,S 또는 N를 함유하고, 임의로 융합된 벤젠을 함유하며, 임의로 탄소수 4까지의 알킬 또는 알콕시, 하이드록시, 니트로, 카바모일 또는 우레이도에 의해 일치환되는, 4급 질소에 부착된 5-또는 6- 원의 방향족 그룹을 나타내며; Y³및 Y⁴는 각기 독립적으로 C1-6-알킬을 나타내거나, Y³및 Y⁴가 함께는 C3-6-알킬렌이며; Y5는 C1-6-알킬이고; 단, R¹이 그룹 OY¹또는 OY²이고 동시에 R³가 그룹 W(여기서 X³. 산소이고 T는 메틸렌 또는 카보닐이다)일 경우에, R²는 그룹 OCOO 또는 치환된 N-원자를 함유하며; 잔기 R⁴, R5및 R6는 각기 독립적으로 잔기 R¹, R², 및 R³에서 정의한 바와 같으나, 단, 그룹 W에서 잔기 - N+RA-대신에 이탈그룹이 존재하고; 잔기 R7, R8및 R9는 각기 독립적으로잔기 R¹, R² 및 R³에서 정의한 바와 같으나, 단 그룹 U 및 V 중의 하나 대신에 하이드록시 그룹 또는 아미노 그룹이 존재하며; R01, R02및 R03는 각기 독립적으로 잔기 R¹, R²및 R³에서 정의한 바와 같으나, 단, 그룹 W에서 그룹 - N+RA-대신에 그룹 - N(Y³ Y⁴)이 존재한다.
제1항에 있어서, R¹이 그룹 U이고, R²가 그룹 V이며 R³가 그룹 W인 방법.
제1 또는 2항에 있어서, R¹이 옥타데카노일시, 옥타데실카바모일옥시, 옥타데실옥시, 옥타데실옥시포아미도, N-이소프로필옥타데실옥시포름아미도 또는 1-이소프로필-3-옥타데실우레이동도인 방법.
제1항에 있어서, R²가 아세트아미도, 메톡시포름아미도, 메톡시, 메틸카바모일옥시 또는 메톡시카보닐옥시인 방법.
제1항에 있어서, R³가 [4-(트리메틸암모니오)-n-부티릴옥시]클로라이드, [2-(1-메틸피레리디니오)-에톡시카보닐옥시]클로라이드, [4-(3-티아졸리오)-n-부톡시]-브로마이드, [4-(트리메틸암모니오)-n-부톡시] 브로마이드 또는 [4-(3-메틸이미다졸리오)-n-부톡시] 브로마이드인 방법.
제1항에 있어서, R¹이 옥타데카노일옥시, 옥타데실카바모일옥시, 옥타데실옥시, 옥타데실옥시포름아미도, N-이소프로필옥타데실포름아미도 또는 1-이소프로필-3-옥타데실우레이도이고 ; R²가 아세트아미도, 메톡시포름아미도, 메톡시, 메틸카바모일옥시 또는 메톡시카보닐옥시이며 ; R³는 [4-(트리메틸암모니오)-n-부티릴옥시]클로라이드, [2-(1-메틸피페리띠니오)에톡시카보닐옥시]클로라이드, [4-(3-티아졸리오-n-부톡시]브로마이드, [4-(트리메틸암모니오)-n-부톡시]브로마이드 또는 [4-(3-메틸이미다졸리오_-n-부톡시]브로마이드인 방법.
※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860004802A 1985-06-18 1986-06-17 글리세롤 유도체의 제조방법 KR870000282A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH02567/85-3 1985-06-18
CH256785 1985-06-18

Publications (1)

Publication Number Publication Date
KR870000282A true KR870000282A (ko) 1987-02-17

Family

ID=4236705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860004802A KR870000282A (ko) 1985-06-18 1986-06-17 글리세롤 유도체의 제조방법

Country Status (16)

Country Link
US (2) US4863941A (ko)
EP (1) EP0208932A3 (ko)
JP (1) JPS61293954A (ko)
KR (1) KR870000282A (ko)
AR (1) AR242175A1 (ko)
AU (1) AU596593B2 (ko)
DK (1) DK281886A (ko)
ES (1) ES8706595A1 (ko)
FI (1) FI862560A (ko)
HU (1) HU196350B (ko)
IL (1) IL79120A0 (ko)
MC (1) MC1757A1 (ko)
NO (1) NO862403L (ko)
NZ (1) NZ216546A (ko)
PT (1) PT82772B (ko)
ZA (1) ZA864486B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185334A (en) * 1989-07-31 1993-02-09 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
WO1989007099A1 (en) * 1988-02-05 1989-08-10 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
WO1989007100A1 (en) * 1988-02-05 1989-08-10 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
FI97883C (fi) * 1988-07-04 1997-03-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen glyserolijohdannaisen valmistamiseksi
US5273985A (en) * 1988-07-04 1993-12-28 Eisai Co., Ltd. Glycerin derivative and its pharmacological use
GR1000688B (el) * 1989-12-22 1992-10-08 Sod Conseils Rech Applic Μεθοδος παρασκευης παραγωγων γλυκερινης.
JP2604268B2 (ja) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790089A (fr) * 1971-10-14 1973-04-13 Ici Ltd Derives de l'imidazole
US4493832A (en) * 1981-07-03 1985-01-15 Fujisawa Pharmaceutical Co., Ltd. Certain glycerol-phosphoryl choline derivatives, compositions containing same and method of using same
JPS5835194A (ja) * 1981-08-25 1983-03-01 Takeda Chem Ind Ltd カルバミン酸エステル類
JPH0240648B2 (ja) * 1981-08-25 1990-09-12 Takeda Chemical Industries Ltd Ketsushobankatsuseiinshokuseizai
JPS58154512A (ja) * 1982-03-09 1983-09-14 Takeda Chem Ind Ltd 血小板活性化因子抑制剤
DE3212387A1 (de) * 1982-04-02 1983-10-13 Bayer Ag, 5090 Leverkusen Glycerinphosphatide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JPS58192825A (ja) * 1982-05-06 1983-11-10 Takeda Chem Ind Ltd グリセロール誘導体
EP0094586A3 (en) * 1982-05-13 1984-06-06 Ono Pharmaceutical Co., Ltd. Glycerol derivatives, process for preparing same and pharmaceutical composition containing same
JPS5931738A (ja) * 1982-08-17 1984-02-20 Ono Pharmaceut Co Ltd グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤
JPS5988447A (ja) * 1982-11-11 1984-05-22 Ono Pharmaceut Co Ltd グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤
JPS604196A (ja) * 1983-06-22 1985-01-10 Nippon Soda Co Ltd グリセリン誘導体
JPS6081194A (ja) * 1983-10-11 1985-05-09 Takeda Chem Ind Ltd ケトアルキルリン脂質
JPS6081193A (ja) * 1983-10-11 1985-05-09 Takeda Chem Ind Ltd リン脂質
JPS60100544A (ja) * 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
DK160818C (da) * 1983-12-30 1991-10-07 Hoffmann La Roche N-ring-holdige glycerolderivater, fremgangsmaade til fremstilling deraf, anvendelse deraf til fremstilling af et blodpladeaktiveringsfaktorhaemmende middel samt laegemidler indeholdende en saadan forbindelse
DE3586746D1 (de) * 1984-04-03 1992-11-19 Takeda Chemical Industries Ltd Lipidderivate, ihre produktion und verwendung.
JPH06419A (ja) * 1992-06-22 1994-01-11 Amada Co Ltd 工業用ロボットの制御装置
JPH08335194A (ja) * 1995-06-07 1996-12-17 Canon Inc 情報処理装置及び情報処理方法

Also Published As

Publication number Publication date
DK281886D0 (da) 1986-06-16
AR242175A1 (es) 1993-03-31
AU596593B2 (en) 1990-05-10
US4863941A (en) 1989-09-05
FI862560A0 (fi) 1986-06-16
NO862403L (no) 1986-12-19
NZ216546A (en) 1990-03-27
ES8706595A1 (es) 1987-07-16
DK281886A (da) 1986-12-19
JPS61293954A (ja) 1986-12-24
AU5890186A (en) 1986-12-24
EP0208932A3 (de) 1989-11-29
FI862560A (fi) 1986-12-19
MC1757A1 (fr) 1987-04-24
EP0208932A2 (de) 1987-01-21
US5057530A (en) 1991-10-15
IL79120A0 (en) 1986-09-30
PT82772A (en) 1986-07-01
NO862403D0 (no) 1986-06-17
PT82772B (pt) 1989-01-17
ZA864486B (en) 1987-02-25
HUT43803A (en) 1987-12-28
ES556110A0 (es) 1987-07-16
HU196350B (en) 1988-11-28

Similar Documents

Publication Publication Date Title
KR870000282A (ko) 글리세롤 유도체의 제조방법
KR830005140A (ko) 피페리딘 유도체의 제조방법
KR840000540A (ko) N-옥사사이클릴-알킬피페리딘 유도체의 제조방법
IE40243L (en) Imidazolyl derivatives
US3055939A (en) Unsymmetric bis-ammonium salts
KR860002496A (ko) 카보닐 화합물의 제조방법
CA2054544A1 (en) Process for the preparation of piperazine derivatives
US4105666A (en) Piperidine derivatives
ES462700A1 (es) Procedimiento para la preparacion de nuevas 1h-pirazolo(3,4-b)piridinas.
MY104084A (en) Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides.
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
KR850001746A (ko) 퀴나졸린 화합물의 제조방법
KR850001906A (ko) 치환된 페닐설포닐 구아니딘 및 그의 중간체의 제조방법
US4836958A (en) Fluorinated cationic compounds
US5378842A (en) Imidazolium hardeners for proteinaceous materials
KR850005841A (ko) 신규 1,3-디옥소라닐 유도체의 제조방법
KR940011591A (ko) 반응성 프탈로시아닌 염료의 제조방법
AU561575B2 (en) Substituted benzyl-cycloalkenylurea derivatives
US4376788A (en) Basic ethers of 4-hydroxy-benzophenones acting as beta-blocking agents
EP0335408A3 (en) Substituted benzene derivatives, processes for their production and antitumour compositions containing them
DE2332597A1 (de) Neue 6-n-triazinylamino-benzofurane und optische aufheller
US3826800A (en) Basic indazole azo compounds
US3252990A (en) Pyrazolone derivatives
GB917078A (en) Improvements in or relating to piperidine derivatives
GB1139446A (en) Polymers containing n,n-disubstituted vinyloxymethylamine units

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid